To investigate the effects of EA treatment on the Akt/GSK-3β signaling pathway following WD-TBI, Western blot assays were performed to assess cortical levels of p-GSK-3β and upstream BDNF expression, as well as p-Akt and downstream pro-apoptotic Bcl-2-associated X protein (Bax) at 48 h after WD-TBI. Here, AKT1 is linked to Wilson disease.